Dublin, Feb. 10, 2021 (GLOBE NEWSWIRE) -- The "Global Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Region: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
The global pharmacogenomics market will reach $12.83 billion by 2030, growing by 8.1% annually over 2020-2030 driven by increase in adoption of personalized medicine and surge in usage of pharmacogenomics for drug discovery and development amid COVID-19 pandemic.
Highlighted with 88 tables and 83 figures, this 181-page report "Global Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Region: Trend Forecast and Growth Opportunity" is based on a comprehensive research of the entire global pharmacogenomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter's Five Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global pharmacogenomics market in every aspect of the classification from perspectives of Service, Technology, Application, End User, and Region.
Based on Service, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Genotyping
- SNP Identification
- Diagnostics
- Other Services
Based on Technology, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Polymerase Chain Reaction (PCR)
- Microarray
- Sequencing
- Electrophoresis
- Mass Spectrometry
- Other Technologies
Based on Application, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Oncology
- Infectious Diseases
- Neurology/Psychiatry
- Cardiovascular
- Pain Management
- Other Applications
Based on End User, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Hospitals and Clinics
- Pharmaceutical Companies
- Research Institutes
Geographically, the following regions together with the listed national/local markets are fully investigated:
- APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
- Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
- North America (U.S., Canada, and Mexico)
- South America (Brazil, Chile, Argentina, Rest of South America)
- MEA (Saudi Arabia, UAE, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Service, Technology, and Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in global pharmacogenomics market are assayed quantitatively and qualitatively through a Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
- 23andMe, Inc.
- Abbott Laboratories
- Admera Health, LLC
- Agena Biosciences, Inc.
- Astra Zeneca PLC
- Bayer AG
- Becton, Dickinson and Company
- Cancer Genetics, Inc.
- Dynamic DNA Laboratories
- Empire Genomics LLC
- F. Hoffmann-La Roche Ltd
- geneOmbio Technologies Pvt Ltd.
- Genomic Health, Inc.
- Illumina, Inc.
- Laboratory Corporation of America Holdings
- Myriad Genetics Inc.
- Oneome LLC
- Opko Health, Inc.
- Pathway Genomics Corporation
- QIAGEN N.V.
- Quest Diagnostics Incorporated
- Teva Pharmaceuticals Industries Ltd.
- Thermo Fisher Scientific Inc.
- Transgenomic, Inc.
Key Topics Covered:
1 Introduction
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 Market Overview and Dynamics
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter's Five Forces Analysis
3 Segmentation of Global Market by Service
3.1 Market Overview by Service
3.2 Genotyping
3.3 SNP Identification
3.4 Diagnostics
3.5 Other Services
4 Segmentation of Global Market by Technology
4.1 Market Overview by Technology
4.2 Polymerase Chain Reaction (PCR)
4.3 Microarray
4.4 Sequencing
4.5 Electrophoresis
4.6 Mass Spectrometry
4.7 Other Technologies
5 Segmentation of Global Market by Application
5.1 Market Overview by Application
5.2 Oncology
5.3 Infectious Diseases
5.4 Neurology/Psychiatry
5.5 Cardiovascular
5.6 Pain Management
5.7 Other Applications
6 Segmentation of Global Market by End User
6.1 Market Overview by End User
6.2 Hospitals and Clinics
6.3 Pharmaceutical Companies
6.4 Research Institutes
7 Segmentation of Global Market by Region
7.1 Geographic Market Overview 2019-2030
7.2 North America Market 2019-2030 by Country
7.2.1 Overview of North America Market
7.2.2 U.S.
7.2.3 Canada
7.2.4 Mexico
7.3 European Market 2019-2030 by Country
7.3.1 Overview of European Market
7.3.2 Germany
7.3.3 UK
7.3.4 France
7.3.5 Spain
7.3.6 Italy
7.3.7 Russia
7.3.8 Rest of European Market
7.4 Asia-Pacific Market 2019-2030 by Country
7.4.1 Overview of Asia-Pacific Market
7.4.2 Japan
7.4.3 China
7.4.4 Australia
7.4.5 India
7.4.6 South Korea
7.4.7 Rest of APAC Region
7.5 South America Market 2019-2030 by Country
7.5.1 Argentina
7.5.2 Brazil
7.5.3 Chile
7.5.4 Rest of South America Market
7.6 MEA Market 2019-2030 by Country
7.6.1 UAE
7.6.2 Saudi Arabia
7.6.3 South Africa
7.6.4 Other National Markets
8 Competitive Landscape
8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
- 23andMe, Inc.
- Abbott Laboratories
- Admera Health, LLC
- Agena Biosciences, Inc.
- Astra Zeneca PLC
- Bayer AG
- Becton, Dickinson and Company
- Cancer Genetics, Inc.
- Dynamic DNA Laboratories
- Empire Genomics LLC
- F. Hoffmann-La Roche Ltd
- geneOmbio Technologies Pvt Ltd.
- Genomic Health, Inc.
- Illumina, Inc.
- Laboratory Corporation of America Holdings
- Myriad Genetics Inc.
- Oneome LLC
- Opko Health, Inc.
- Pathway Genomics Corporation
- QIAGEN N.V.
- Quest Diagnostics Incorporated
- Teva Pharmaceuticals Industries Ltd.
- Thermo Fisher Scientific Inc.
- Transgenomic, Inc.
9 Investing in Global Market: Risk Assessment and Management
9.1 Risk Evaluation of Global Market
9.2 Critical Success Factors (CSFs)
For more information about this report visit https://www.researchandmarkets.com/r/iizyyb